Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT03848754 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Relapsed Adult AML

Interventions

DRUG: Gemtuzumab Ozogamicin 3 mg/m^2
DRUG: Gemtuzumab Ozogamicin 2 mg/m^2
DRUG: Pracinostat - 45 mg
DRUG: Pracinostat - 60 mg

Sponsor

Medical College of Wisconsin